Novotech, an Asia-Pacific biotech specialist CRO, has acquired U.S. CRO NCGS as part of its expansion program, and can now offer its biotech clients clinical services in the U.S. to support later phase global studies.
 
NCGS, established in 1984 in South Carolina, is a privately held CRO with a biopharma client base and a workforce of about 300 professionals across the U.S.
 
Novotech serves biotechs globally, leveraging deep relationships built with hundreds of Asia-Pacific sites over the last 25 years. NCGS compliments this with a broad U.S. site base and hundreds of investigators with relationships spanning nearly four decades.
 
Novotech CEO Dr. John Moller said, “We are very pleased to acquire such an impressive company with a strong history of quality and delivery in the United States. The company’s growth is a real credit to the knowledge and expertise of founder Nancy Snowden and the exceptional team she has formed.”
 
Moller continued, “This is a strategic move to provide U.S.-based expertise and infrastructure for our U.S. clients wanting trials in APAC and the U.S., and for our APAC clients wanting U.S. clinical programs. Clients will receive seamless service, with a unified approach to systems and SOPs well developed.”
 
Nancy C.G. Snowden, founder and CEO of NCGS, said the company was excited about becoming part of Novotech operations globally and supporting Novotech’s clients with their U.S. clinical programs.
 
“We have a similar cultural fit and focus on excellence, so joining Novotech will be seamless for both ours and Novotech’s clients. Novotech and NCGS have a collaboration history of over a decade which will also support the seamless integration,” said Snowden.
 
“NCGS focuses on complex areas of clinical development; oncology, hematology, infectious disease, and CNS in both adult and pediatric populations. Our lean organizational structure and nimble operational model with highly tenured staff have been specifically designed to overcome the challenges inhibiting our industry today. We have the ability to pivot in real time as the needs of the trial evolve,” Sowden added.